FDA orders clinical hold on Targeted Genetics trial

Share this article:
The FDA has ordered a clinical hold on a Targeted Genetics clinical trial involving tgAAC94, an investigational therapy indicated for treating inflammatory arthritis. The hold came after one subject experienced a serious adverse event, but the company says there is insufficient information to draw conclusions as to the cause.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.